Sex differences in 123I-mIBG scintigraphy imaging techniques in patients with heart failure

Expert Rev Med Devices. 2023 Jul-Dec;20(9):769-778. doi: 10.1080/17434440.2023.2239139. Epub 2023 Jul 24.

Abstract

Background: 123I-mIBG-scintigraphy could be a useful stratifying tool for patients with heart failure (HF). The purpose of this retrospective study is to evaluate whether there are differences between men and women with HF in terms of the prediction of cardiac arrhythmic events (AE).

Research and methods: A total of 306 patients, before implantable-cardioverter-defibrillator (ICD) implantation, were evaluated. They underwent 123I-mIBG-scintigraphy and an evaluation of the results was performed after 85 months of follow-up. Early and late planar and SPECT cardiac images were acquired. Heart-to-mediastinum ratio (HM) for planar images and the sum of the segmental scores (SS) for SPECT were calculated.

Results: In the general population, age, early SS (ESS), late SS (LSS), and ejection fraction (EF) were statistically significant for the prediction of AE at Cox regression, while early and late HM (eHM,lHM) were not significative for the prediction of AE. Population was divided into females and males and univariate analysis was conducted separately for the two cohorts: no significant variables for prediction of AE were found in females. For males, ESS, LSS, EF, and late HM were statistically significant predictors of AE. The overall survival was similar in males and females, but the risk of AE is lower in males than in females.

Conclusions: 123I-mIBG represents a more effective tool for the prediction of AE in male patients than in women.

Keywords: Cardiac innervation; ESS; HM; SPECT; cardiac arrhythmic events; heart failure; mIBG.

MeSH terms

  • 3-Iodobenzylguanidine*
  • Female
  • Heart
  • Heart Failure* / diagnostic imaging
  • Humans
  • Male
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Retrospective Studies
  • Sex Characteristics

Substances

  • 3-Iodobenzylguanidine
  • Iodine-123
  • Radiopharmaceuticals